January 27, 2012
Daniel Bertholet of Endeavour Vision speaks at SECA event

 
December 19, 2011
CommProve achieves key milestones in 2011

 
December 8, 2011
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®

 
November 22, 2011
ComputerWorld: 7 hot storage startups to watch

 
November 15, 2011
CommProve launches BCN RAN Insight for real-time RAN congestion management

 
November 3, 2011
CommProve launches CommProve NetLedge p20K solution

 
November 2, 2011
Storage Industry Veteran Mike Wall Joins Amplidata Board

 
October 27, 2011
BIND Announces New $47.25 Million Financing To Accelerate Multi-Product Pipeline

 
October 10, 2011
Dominique Pitteloud and Franck Tetzlaff from Kobojo is interviewed for nouvu.ch

 
October 10, 2011
Amplidata and École Polytechnique Fédérale de Lausanne build Live Video Archive of Montreux Jazz Festival Legends

 
September 30, 2011
Symetis’ ACURATE TA™ Aortic Bioprosthesis Receives CE Mark Certification on Sept. 30th 2011

 
September 23, 2011
Investor Allstars Awards Winners Announced

 
September 15, 2011
Kobojo sets up in Spain and expands its leadership in Latin America

 
July 25, 2011
TechCrunch: Atomico, Conway, And Founders Fund Put $10 Million Into Quid; Max Levchin Joins Board

 
July 19, 2011
Paper.li THE BLOG: One Billion Articles Featured by Paperli Publishers

 
June 1, 2011
Retailo kauft die giftmobile GmbH – und komplettiert so das Angebot

 
May 26, 2011
Ex-Electronic Arts Executive Gerhard Florin joins Kobojo

 
May 20, 2011
CommProve releases real-time RAN congestion management solution

 
May 19, 2011
Sequans Ships Ten Millionth 4G Chip

 
May 18, 2011
Symetis reports on its trans-apical ACURATE TA™ clinical

 
May 4, 2011
Allergan and Molecular Partners enter into an exclusive license agreement for MP0112 for the treatment of retinal diseases

 
April 28, 2011
Molecular Partners reports positive results from its first clinical studies

 
April 26, 2011
Kobojo completes the first round of its $7.5 million (€5.3 million) fund-raising programme with Endeavour Vision and IDinvest Partners

 
April 15, 2011
Sequans Communications Announces Pricing of Initial Public Offering

 
April 12, 2011
Amplidata and ReelData join forces to enable scalable, active archive solutions for media and entertainment

 
April 6, 2011
BIND Biosciences Receives 2011 Edison Award

 
April 5, 2011
Amplidata introduces AmpliStor, optimized object storage for massive-scale unstructured data

 
February 23, 2011
BIND Biosciences named one of MIT's Technology Review 2011 TR50 - second year in a row

 
February 16, 2011
Interview with Lars Pedersen

 
February 15, 2011
BroadHop and CommProve Team to Deliver Industry’s First End-to-End Intelligent Application and Subscriber RAN Congestion Management

 
February 14, 2011
CommProve and 2operate partner to provide powerful network troublehsooting solution

 
February 11, 2011
BIND Biosciences featured in the London Times

 
February 8, 2011
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®

 
January 13, 2011
Amplidata Attacks U.S. and World Cloud Market with AmpliStor

 
January 11, 2011
SmallRivers Announces $2.1M Financing Round to Expand Paper.li Globally

 
January 7, 2011
BIND Biosciences Initiates Phase 1 Clinical Study of BIND-014

 
January 4, 2011
PneumRx, Inc. Raises $33 Million in Capital

 
Transformational Agreement Supports BIND-014 Through Late-Stage Clinical Efficacy Study in Cancer and Advances a Second Product Candidate into Clinical Development

BIND's Accurin Targeted Therapeutics Concentrate at the Site of Disease, Resulting in High Efficacy and Low Toxicity


Cambridge, Mass., USA, October 27, 2011 - BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called AccurinsTM, today announced a $47.25 million financing from RUSNANO, existing investors, and additional new investors. RUSNANO, a global $10 billion investment fund focused on nanotechnology, entered as a significant new investor in this financing which will advance BIND's pipeline of novel drug candidates for cancer and other diseases.

BIND will use the proceeds from this financing to accelerate and expand the company's pipeline of highly selective, targeted drug candidates which are based o ...

more...
© Endeavour Vision SA 2006-2012 Terms & Conditions